Cardiovascular effects of cannabinoids

Pharmacology and Therapeutics

Volumn 95, Issue 2, 2002, Pages 191-202

  Randall, Michael D ^a   Harris, David ^a   Kendall, David A ^a   Ralevic, Vera ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anandamide; Endocannabinoids; Endothelium; Gap junctions; Vasorelaxation

Indexed keywords

ADENYLATE CYCLASE; AUTACOID; CALCIUM CHANNEL; CANNABINOID; POTASSIUM CHANNEL; POTASSIUM ION; SODIUM CHANNEL; SODIUM ION; VANILLOID RECEPTOR;

ARTICLE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; DEPRESSOR RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GAP JUNCTION; HEMORRHAGIC SHOCK; HYPOTENSION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRESSOR RESPONSE; PRIORITY JOURNAL; SEPTIC SHOCK; VASODILATATION;

EID: 0036669502     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00258-9     Document Type: Review

References (87)

1. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 100:2000;685-688.
2. 1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 7:2001;827-832.
3. Benowitz N.L., Jones R.T. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther. 18:1975;287-297.
4. Benowitz N.L., Rosenberg J., Rogers W., Bachman J., Jones R.T. Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther. 25:1979;440-446.
5. Bilfinger T.V., Salzet M., Fimiani C., Deutsch A., Tramu G., Stefano G.B. Pharmacological evidence for anandamide amidase in human cardiac vascular tissues. Int J Cardiology. 64:1998;S15-S22.
6. Bonhaus D.W., Chang L.K., Kwan J., Martin G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther. 287:1998;884-888.
7. 2 receptor messenger RNAs during embryonic development in the rat. Neuroscience. 82:1998;1131-1149.
8. Calignano A., La Rana G., Beltramo M., Makriyannis A., Piomelli D. Potentiation of anandamide hypotension by transport inhibitor, AM404. Eur J Pharmacol. 337:1997;R1-R2.
9. 1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br J Pharmacol. 123:1998;968-974.
10. Chaytor A.T., Evans W.H., Griffith T.M. Central role of heterocellular gap junctional communication in endothelium-dependent relaxations of rabbit arteries. J Physiol (Lond). 508:1998;561-573.
11. Chaytor A.T., Martin P.E.M., Evans W.H., Randall M.D., Griffith T.M. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol (Lond). 520:1999;539-550.
12. Chen Y., McCarron R.M., Ohara Y., Bembry J., Azzam N., Lenz F.A., Shohmani E., Mechoulam R., Spatz M. Human brain capillary endothelium-2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res. 87:2000;323-327.
13. 1) receptor expression is associated with mesenteric resistance vessels but not thoracic aorta in the rat. Br J Pharmacol. 125:1998;95P.
14. Derkinderen P., Toutant M., Burgaya F., Le Bert M., Siciliano J.C., De Franciscis V., Gelman M., Girault J.-A. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science. 273:1996;1719-1722.
15. Deutsch D.G., Goligorsky M.S., Schmid P.G., Krebsbach R.J., Schmid H.H.O., Das S.K., Dey S.K., Arreaza G., Thorup C., Stefano G., Moore L.C. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 100:1997;1538-1546.
16. Dewey W.L. Cannabinoid pharmacology. Pharmacol Rev. 38:1986;151-178.
17. Di Marzo V., Bisogno T., DePetrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem. 264:1999;258-267.
18. 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol (Heart Circ). 38:1995;H1859-H1864.
19. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 48:1995;443-450.
20. Felder C.C., Joyce K.E., Briley E.M., Glass M., Mackie K.P., Fahey K.J., Cullinan G.J., Hunden D.C., Johnson D.W., Chaney M.O., Koppel G.A., Brownstein M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther. 284:1998;291-297.
21. Fleming I., Schermer B., Popp R., Busse R. Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol. 126:1999;949-960.
22. Gardiner S.M., March J.E., Kemp P.A., Bennett T. Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. Br J Pharmacol. 133:2001;445-453.
23. Garland C.J., Plane F., Kemp B.K., Cocks T.M. Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol Sci. 16:1995;23-30.
24. 2+ channel current. Am J Physiol (Heart Circ). 45:1999;H2085-H2093.
25. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., Hipkin R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol. 57:2000;1045-1050.
26. Han S.-P., Naes L., Westfall T.C. Inhibition of periarterial nerve stimulation-induced vasodilation of the mesenteric arterial bed by CGRP (8-37) and CGRP receptor desensitization. Biochem Biophys Res. 168:1990;786-791.
27. Harris D., Kendall D.A., Randall M.D. Effects of AM404, a cannabinoid reuptake inhibitor, on EDHF-mediated relaxations in the rat isolated mesentery. Br J Pharmacol. 125:1998;15P.
28. +-relaxation. Eur J Pharmacol. 401:2000;119-128.
29. Harris D., McCulloch I.A., Kendall D.A., Randall M.D. Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol (Lond). 539:2002;893-903.
30. Himmi T., Perrin J., Ouzzani T.E., Orsini J.-C. Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol. 359:1998;49-54.
31. 1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 90:1999;923-931.
32. Hohmann A.G., Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1999;1171-1175.
33. o to inhibition of adenylyl cyclase in carotid artery smooth muscle. Br J Pharmacol. 128:1999;597-604.
34. 1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 118:1996;2023-2028.
35. 2+-induced relaxation. J Pharmacol Exp Ther. 289:1999;245-250.
36. 2 receptors. Proc Natl Acad Sci USA. 96:1999;14136-14141.
37. Jarai Z., Wagner J.A., Goparaju S.K., Wang L., Razadan R.K., Sugiura T., Zimmer A.M., Bonner T.I., Zimmer A., Kunos G. Cardiovascular effects of 2-arachidonoyl glycerol in anaesthetized mice. Hypertension. 35:2000;679-684.
38. Lake K.D., Martin B.R., Kunos G., Varga K. Cardiovascular effects of anandamide in anaesthetized and conscious normotensive rats. Hypertension. 29:1997;1204-1210.
39. 1 receptors in the rat and mouse. Eur J Pharmacol. 391:2000;151-161.
40. 1 receptor knockout mice. Science. 283:1999;401-404.
41. Liu J., Gao B., Mirshahi F., Sanyal A.J., Khanolkar A.D., Makriyannis A., Kunos G. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J. 346:2000;835-840.
42. Maccarrone M., Bari M., Lorenzon T., Bisogno T., Di Marzo V., Finazzi-Agro A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem. 275:2000;13484-13492.
43. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol. 44:1993;498-503.
44. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci. 15:1995;6552-6561.
45. Mechoulam R., Fride E., Ben-Shabat S., Meiri U., Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in the rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol. 362:1998;R1-R3.
46. Millns P., Chapman V., Kendall D.A. Cannabinoid inhibition of capsaicin-induced calcium response in rat dorsal root ganglion cells. Br J Pharmacol. 132:2001;969-971.
47. Mombouli J.-V., Vanhoutte P.M. Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends Pharmacol Sci. 18:1997;252-256.
48. Niederhoffer N., Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol. 126:1999;457-466.
49. Pertwee R.G., Fernando S.R., Nash J.E., Coutts A.A. Further evidence for the presence of cannabinoid CB1 receptors in guinea pig small intestine. Br J Pharmacol. 118:1996;2199-2205.
50. 1 receptors in mouse vas deferens. Eur J Pharmacol. 296:1996;169-172.
51. Plane F., Holland M., Waldron G.J., Garland C.J., Boyle J.P. Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol. 121:1997;1509-1512.
52. Pratt P.F., Hillard C.J., Edgemond W.S., Campbell W.B. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol (Heart Circ). 43:1998;H375-H381.
53. Ralevic V., Kendall D.A. Cannabinoid modulation of sympathetic neurotransmission in the rat isolated mesenteric arterial bed. J Auton Nerv Syst. 82:2000;76.
54. Ralevic V., Kendall D.A. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat isolated mesenteric arterial bed. Eur J Pharmacol. 418:2001;117-125.
55. Ralevic V., Kendall D.A., Bennett T., Gardiner S.M. Comparison of the effects of anandamide and methanandamide in bioassays. Br J Pharmacol. 129:2000;141P.
56. Ralevic V., Kendall D.A., Randall M.D., Zygmunt P.M., Movahed P., Högestatt E.D. Vanilloid receptors on capsaicin-sensitive nerves mediate relaxation to methanandamide in the rat isolated mesenteric bed. Br J Pharmacol. 130:2000;1483-1488.
57. Randall M.D., Kendall D.A. The involvement of an endogenous cannabinoid in EDHF-mediated vasorelaxation in the rat coronary vasculature. Eur J Pharmacol. 335:1997;205-209.
58. Randall M.D., Kendall D.A. Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery. Eur J Pharmacol. 346:1998;51-53.
59. Randall M.D., Alexander S.P.H., Bennett T., Boyd E.A., Fry J.R., Gardiner S.M., Kemp P.A., McCulloch A.I., Kendall D.A. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun. 229:1996;114-120.
60. Randall M.D., McCulloch A.I., Kendall D.A. Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. Eur J Pharmacol. 333:1997;191-197.
61. Randall M.D., Harris D., Darker I.T., Millns P.J., Kendall D.A. Endocannabinoids: endothelium-derived vasodilators. Vanhoutte P.M. Endothelium-Dependent Hyperpolarizations. 1999;149-155 Harcourt, Amsterdam.
62. 1 receptors. Pain. 75:1998;111-119.
63. Ross R.A., Brockie H.C., Pertwee R.G. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamine. Eur J Pharmacol. 401:2000;121-130.
64. Ross R.A., Coutts A.A., McFarlane S.M., Anavi-Goffer S., Irving A.J., Pertwee R.G., MacEwan D.J., Scott R.H. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology. 40:2001;221-232.
65. Sañudo-Peña M.C., Strangman N.M., Mackie K., Walker J.M., Tsou K. CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Acta Pharmacol Sin. 20:1999;1115-1120.
66. Smart D., Jerman J.C. Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol Sci. 21:2000;134.
67. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol. 129:2000;227-230.
68. Stark P., Dews P.B. Cannabinoids. II. Cardiovascular effects. J Pharmacol Exp Ther. 214:1980;131-138.
69. Stein E.A., Fuller S.A., Edgemond W.S., Campbell W.B. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamine (anandamide), in the rat. Br J Pharmacol. 119:1996;107-114.
70. 1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator. Biochem Biophys Res Commun. 243:1998;838-843.
71. Szolcsányi J. Are cannabinoids endogenous ligands for the VR1 capsaicin receptor. Trends Pharmacol Sci. 21:2000;41-42.
72. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
73. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 78:1997;43-50.
74. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol. 278:1995;279-283.
75. Varga K., Lake K.D., Huangfu D., Guyenet P.G., Kunos G. Mechanism of the hypotensive action of anandamide in anaesthetised rats. Hypertension. 28:1996;682-686.
76. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12:1998;1035-1044.
77. 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol. 28:1996;332-336.
78. 1 cannabinoid receptors in haemorrhagic shock. Nature. 390:1997;518-521.
79. Wagner J.A., Varga K., Jarai Z., Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 33:1999;429-434.
80. 1 receptors. Eur J Pharmacol. 423:2001;203-210.
81. Wang Y., Liu Y., Hashiguchi T., Kitajima I., Yamakuchi M., Shimizu H., Matsuo S., Imaizuma H., Maruyama I. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem. 294:2001;73-82.
82. White R., Hiley C.R. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol. 122:1997;1573-1584.
83. White R., Hiley C.R. The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br J Pharmacol. 125:1998;533-541.
84. Zygmunt P.M., Högestatt E.D., Waldeck K., Edwards G., Kirkup A.J., Weston A.H. Studies on the effects of anandamide in the rat hepatic artery. Br J Pharmacol. 122:1997;1679-1686.
85. Zygmunt P.M., Petersson J., Anderssson D.A., Chuang H.-H., Sørgård M., Di Marzo V., Julius D., Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.
86. Zygmunt P.M., Chuang H., Movahed P., Julius D., Högestätt E.D. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol. 396:2000;39-42.
87. Zygmunt P.M., Julius D., Di Marzo V., Högestätt E.D. Anandamide - the other side of the coin. Trends Pharmacol Sci. 21:2000;43-44.